Navigation Links
Nabriva Therapeutics Announces Appointment of New CEO
Date:7/2/2008

VIENNA, Austria, July 3 /PRNewswire/ -- Nabriva Therapeutics, a specialist in antibiotics development, announces that Dr. George Golumbeski has been appointed as Chief Executive Officer of the Company.

Dr. Golumbeski brings to the team nearly twenty years of industry experience serving most recently as Vice President of Business Development, Licensing & Strategy for the oncology business unit at Novartis. In this position he was responsible for the full array of business development activities leading several transactions which have resulted in projects currently in Phase III studies. While at Novartis, Dr. Golumbeski also served as a member of the Executive Committee which oversees overall oncology business performance. Prior to his tenure at Novartis, he led transactions which have resulted in two products that have been approved or are in registration in the US and the EU.

"I am excited to join Nabriva at this important stage of its growth. The Company's highly differentiated compounds have the potential to address the significant need for new classes of effective antibiotics. Furthermore, the team at Nabriva is highly experienced with a deep understanding and enthusiasm for the development of novel antibiotics," commented Dr. Golumbeski.

David Chiswell, Chair of the Supervisory Board, added, "We are pleased to welcome George to the team. His leadership skills combined with his strategic and business development insight will help position Nabriva as one of the leading specialist companies in antibiotics development."

About Nabriva Therapeutics:

Headquartered in Vienna, Nabriva Therapeutics is engaged in the discovery and development of innovative antibacterial agents addressing unmet medical need in the hospital and community setting. The company has two compounds currently in clinical trials and expects to have a third compound enter clinical trials later this year. The lead compound, BC-3205, is a parenterally and orally available pleuromutilin which is first in class and has significant market potential in multiple indications (eg. SSSI & CAP). All of Nabriva's programs are derived from compounds generated in-house through discovery activity and the company maintains an ongoing effort in medicinal chemistry.

The Company was founded in January 2006 as a spin-out of Sandoz GmbH Kundl. The spin-out was led by Nomura Phase4 Ventures with a Series A financing of EUR42 million with a syndicate that included HBM Partners, GLSV, The Wellcome Trust and Novartis Venture Fund.

Contacts:

Claudia Karner,

Tel: +43(0)1-74093-1240,

e-mail: claudia.karner@nabriva.com


'/>"/>
SOURCE Nabriva Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
2. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
3. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
4. Tobira Therapeutics Inc. Announces Senior Management Team
5. Duska Therapeutics Obtains Standard & Poors Listing
6. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
7. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
8. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
9. Commercial Launch of Lexiscan(TM) (Regadenoson) Injection Triggers $10 Million Milestone Payment from TPG-Axon Capital to CV Therapeutics
10. Barrier Therapeutics to Merge Into Stiefel Laboratories
11. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... the business of innovation is taking over sports. On Thursday, December 15th a ... how technology is disrupting the playing field at a Smart Talk session. Smart ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and type 2 ... license for a novel adeno-associated virus (AAV) vector ... Kay , M.D., Ph.D., at Stanford University. The ... of its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... that provide essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, ... The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard 204-pin ...
(Date:12/8/2016)...  Anaconda BioMed S.L., a pre-clinical stage medical device ... neuro-thrombectomy system for the treatment of Acute Ischemic Stroke ... to join its Scientific Advisory Board (SAB). The SAB ... scientific and clinical experts to Anaconda BioMed S.L., as ... ® to its clinical phase. The SAB is ...
Breaking Biology Technology:
(Date:11/28/2016)... LONDON , Nov. 28, 2016 ... at a rate of 16.79%" The biometric system ... to grow further in the near future. The biometric ... 32.73 billion in 2022, at a CAGR of 16.79% ... biometrics system, integration of biometric technology in smartphones, rising ...
(Date:11/22/2016)... According to the new market research report "Biometric System Market by Authentication ... (Hardware and Software), Function (Contact and Non-contact), Application, and Region - Global ... from USD 10.74 Billion in 2015 to reach USD 32.73 Billion by ... Continue Reading ... ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
Breaking Biology News(10 mins):